<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534651</url>
  </required_header>
  <id_info>
    <org_study_id>EK1265</org_study_id>
    <nct_id>NCT00534651</nct_id>
  </id_info>
  <brief_title>Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease</brief_title>
  <official_title>Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of orally given paracetamol on the&#xD;
      vascular function and on 24-hour blood pressure in patients with coronary artery disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic pain diseases (e.g. osteoarthritis) are dependent on effective&#xD;
      medication. NSAIDs are very effective in lowering pain in these patients. Recently there has&#xD;
      aroused major concern with regard to cardiovascular side effects and safety, especially in&#xD;
      selective cyclooxygenase-2 inhibitors (coxibs) but also in &quot;regular&quot; NSAIDs.&#xD;
&#xD;
      At the moment, there is a big confusion, whether these drugs still should be used, especially&#xD;
      in patients with known coronary artery disease. Physicians now try to switch to high dose&#xD;
      paracetamol, despite the weaker efficacy in pain relieve, because this drug is considered&#xD;
      generally as not harmful.&#xD;
&#xD;
      As there is very few information on the cardiovascular effect of this drug, we plan to&#xD;
      perform this study and investigate the impact of paracetamol on endothelial function, an&#xD;
      important cardiovascular surrogate marker, on inflammatory markers and on oxidative stress in&#xD;
      patients with coronary artery disease on top of standard medication, including aspirin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy endpoint: To investigate the effect of paracetamol on endothelial function as compared to placebo in patients with stable coronary artery disease.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>primary safety endpoint: to evaluate the effect of paracetamol on 24-hour systolic and diastolic blood pressure as compared to placebo in patients with stable coronary artery disease.</measure>
    <time_frame>2 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of paracetamol on markers of inflammation and oxidative stress as well as platelet function</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">37</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Endothelial Function</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 30 - 80 years&#xD;
&#xD;
          -  History of coronary artery disease (documented by coronary angiogram, nuclear imaging,&#xD;
             positive stress test)&#xD;
&#xD;
          -  Stable cardiovascular medication for at least 1 month&#xD;
&#xD;
          -  Written obtained informed consent&#xD;
&#xD;
        Exclusion Criteria:- myocardial infarction, unstable angina, stroke within 3 months prior&#xD;
        to study entry&#xD;
&#xD;
          -  coronary intervention/revascularisation procedure within 3 months prior to study entry&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;50%&#xD;
&#xD;
          -  Other analgesics (Platelet inhibition therapy with Aspirin 100mg/d will be continued)&#xD;
&#xD;
          -  Long acting nitrates&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Chronic heart failure (&gt; NYHA II)&#xD;
&#xD;
          -  Ventricular tachyarrhythmias&#xD;
&#xD;
          -  Renal failure (serum creatinine &gt;200umol)&#xD;
&#xD;
          -  Liver disease (ALT or AST &gt;100 IU), especially acute hepatitis&#xD;
&#xD;
          -  Hyperbilirubinemia&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Oral Anticoagulation&#xD;
&#xD;
          -  Concomitant therapy with Phenobarbital, Phenytoin, Carbamazepin, Isonicotinic Acid,&#xD;
             Chloramphenicol Chlorzoxazone, Zidovudine, Salicylamide&#xD;
&#xD;
          -  Insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Anemia (Hb&lt;10 g/dl)&#xD;
&#xD;
          -  Known allergies on Paracetamol&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Malignancy (unless healed or remission &gt; 5 years)&#xD;
&#xD;
          -  Symptomatic hypotension, hypertension &gt;160/100 mmHg&#xD;
&#xD;
          -  Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)&#xD;
&#xD;
          -  Participation in another study within the last month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ruschitzka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

